CUREVAC NV (5CV.DE) Stock Fundamental Analysis
FRA:5CV - NL0015436031 - Common Stock
4.59 EUR
-0.05 (-1.12%)
We assign a fundamental rating of 6 out of 10 to 5CV. 5CV was compared to 73 industry peers in the Biotechnology industry. 5CV is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 5CV has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year 5CV was profitable.
In the past year 5CV had a positive cash flow from operations.
In the past 5 years 5CV reported 4 times negative net income.
In multiple years 5CV reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 24.34%, 5CV belongs to the best of the industry, outperforming 94.52% of the companies in the same industry.
With an excellent Return On Equity value of 27.94%, 5CV belongs to the best of the industry, outperforming 93.15% of the companies in the same industry.
5CV has a Return On Invested Capital of 24.75%. This is amongst the best in the industry. 5CV outperforms 97.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROIC | 24.75% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 34.50%, 5CV belongs to the best of the industry, outperforming 93.15% of the companies in the same industry.
5CV has a better Operating Margin (37.87%) than 91.78% of its industry peers.
5CV's Gross Margin of 87.59% is amongst the best of the industry. 5CV outperforms 80.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 5CV is creating value.
Compared to 1 year ago, 5CV has about the same amount of shares outstanding.
Compared to 5 years ago, 5CV has more shares outstanding
Compared to 1 year ago, 5CV has an improved debt to assets ratio.
2.2 Solvency
5CV has an Altman-Z score of 9.95. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
5CV has a better Altman-Z score (9.95) than 84.93% of its industry peers.
The Debt to FCF ratio of 5CV is 0.26, which is an excellent value as it means it would take 5CV, only 0.26 years of fcf income to pay off all of its debts.
5CV's Debt to FCF ratio of 0.26 is amongst the best of the industry. 5CV outperforms 95.89% of its industry peers.
5CV has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
5CV's Debt to Equity ratio of 0.05 is fine compared to the rest of the industry. 5CV outperforms 69.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Altman-Z | 9.95 |
ROIC/WACC3.45
WACC7.18%
2.3 Liquidity
5CV has a Current Ratio of 7.65. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
5CV has a better Current ratio (7.65) than 87.67% of its industry peers.
A Quick Ratio of 7.64 indicates that 5CV has no problem at all paying its short term obligations.
The Quick ratio of 5CV (7.64) is better than 89.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 166.39% over the past year.
5CV shows a strong growth in Revenue. In the last year, the Revenue has grown by 787.58%.
Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
3.2 Future
5CV is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.50% yearly.
The Revenue is expected to decrease by -11.17% on average over the next years. This is quite bad
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.17%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.67 indicates a rather cheap valuation of 5CV.
Compared to the rest of the industry, the Price/Earnings ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 95.89% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of 5CV to the average of the S&P500 Index (27.08), we can say 5CV is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for 5CV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.67 | ||
| Fwd PE | N/A |
4.2 Price Multiples
5CV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 5CV is cheaper than 95.89% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 5CV is valued cheaply inside the industry as 94.52% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.22 | ||
| EV/EBITDA | 2.91 |
4.3 Compensation for Growth
5CV has a very decent profitability rating, which may justify a higher PE ratio.
5CV's earnings are expected to decrease with -31.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
5. Dividend
5.1 Amount
No dividends for 5CV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (8/29/2025, 7:00:00 PM)
4.59
-0.05 (-1.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.6%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.03B
Analysts72.31
Price Target4.22 (-8.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.37%
Min EPS beat(2)-18.68%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)39.95%
Min EPS beat(4)-18.68%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)0.33%
EPS beat(12)5
Avg EPS beat(12)-6.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.68%
Min Revenue beat(2)-86.88%
Max Revenue beat(2)118.24%
Revenue beat(4)3
Avg Revenue beat(4)139.54%
Min Revenue beat(4)-86.88%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)58.85%
Revenue beat(12)5
Avg Revenue beat(12)30.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.89%
PT rev (3m)-25.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-302.78%
EPS NY rev (1m)0%
EPS NY rev (3m)8.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.67 | ||
| Fwd PE | N/A | ||
| P/S | 1.97 | ||
| P/FCF | 7.22 | ||
| P/OCF | 6.58 | ||
| P/B | 1.6 | ||
| P/tB | 1.66 | ||
| EV/EBITDA | 2.91 |
EPS(TTM)0.81
EY17.65%
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)0.64
FCFY13.85%
OCF(TTM)0.7
OCFY15.19%
SpS2.33
BVpS2.87
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROCE | 29.12% | ||
| ROIC | 24.75% | ||
| ROICexc | 70.54% | ||
| ROICexgc | 78.69% | ||
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% | ||
| FCFM | 27.34% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Debt/EBITDA | 0.15 | ||
| Cap/Depr | 74.88% | ||
| Cap/Sales | 2.65% | ||
| Interest Coverage | 85.86 | ||
| Cash Conversion | 72.42% | ||
| Profit Quality | 79.25% | ||
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 | ||
| Altman-Z | 9.95 |
F-Score8
WACC7.18%
ROIC/WACC3.45
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.17%
EBIT growth 1Y168.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y142.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y162.99%
OCF growth 3YN/A
OCF growth 5YN/A